We are live on ! Find out more
TCM

Tang Capital Management Portfolio holdings

AUM $1.97B
1-Year Est. Return 125.1%
This Fund
S&P 500
This Quarter Est. Return
+5.91%
1 Year Est. Return
+125.1%
3 Year Est. Return
+474.48%
5 Year Est. Return
+595.08%
10 Year Est. Return
+2,831.44%
AUM
$497M
AUM Growth
+$15.6M
Cap. Flow
+$142M
Cap. Flow %
28.52%
Top 10 Hldgs %
77%
Holding
31
New
11
Increased
2
Reduced
5
Closed
2

Top Buys

Rank Stock Value
1
ALLK
Allakos
ALLK
+$108M
2
ANIP icon
ANI Pharmaceuticals
ANIP
+$12.9M
3
RDUS
Radius Health, Inc.
RDUS
+$11.2M
4
LEGN icon
Legend Biotech
LEGN
+$10.1M
5
IMGN
Immunogen Inc
IMGN
+$9.32M

Top Sells

Rank Stock Value
1
APVO icon
Aptevo Therapeutics
APVO
+$27.2M
2
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$6.5M
3
CRVS icon
Corvus Pharmaceuticals
CRVS
+$2.51M
4
NXTC icon
NextCure
NXTC
+$2.02M
5
LJPC
La Jolla Pharmaceutical Company
LJPC
+$1.84M

Sector Composition

Rank Sector Weight
1 Healthcare 93.65%
2 Financials 1.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASLN
26
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$2.3M 0.46%
51,373
+26,990
+111% +$1.62M
EQ icon
27
Equillium
EQ
$133M
$2.26M 0.45%
600,000
– –
RLMD icon
28
Relmada Therapeutics
RLMD
$519M
$1.33M 0.27%
59,122
-40,878
-41% -$909K
CTMX icon
29
CytomX Therapeutics
CTMX
$753M
$660K 0.13%
+152,345
New +$892K
APVO icon
30
Aptevo Therapeutics
APVO
$5.21M
– –
-3
Closed -$27.2M
NXTC icon
31
NextCure
NXTC
$23.8M
– –
-25,000
Closed -$2.02M
1
2

Similar funds

HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return

Tang Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, Tang Capital Management held 31 positions worth $497M, up 3.2% from $482M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Tang Capital Management deployed $142M of net new capital in Q4 2021, opening 11 new positions and adding to 2 existing holdings. Its largest new stake was Allakos: 1,323,393 shares worth $13M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 96% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Odonate Therapeutics, Inc. Common Stock, an estimated $6.5M trimmed.

  • Tang Capital Management's largest Q4 2021 buy was Allakos: 1,323,393 shares worth $13M.
  • Tang Capital Management added most to ASLAN Pharmaceuticals Limited American Depositary Shares in Q4 2021, an estimated $1.62M increase.
  • Tang Capital Management's biggest Q4 2021 reduction was Odonate Therapeutics, Inc. Common Stock, cutting an estimated $6.5M.
  • Tang Capital Management fully exited Aptevo Therapeutics in Q4 2021, selling an estimated $27.2M.
  • Tang Capital Management's ten largest holdings make up 77% of its $497M portfolio in Q4 2021.
  • Tang Capital Management opened 11 new positions and closed 2 in Q4 2021.
  • Tang Capital Management's portfolio value rose 3.2% quarter-over-quarter to $497M.

Based on Tang Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.